ArriVent's first-line EGFR exon 20 NSCLC phase 3 misses its primary endpoint
- Fierce Biotech reports that ArriVent's phase 3 FURVENT trial of the EGFR inhibitor firmonertinib missed its primary progression-free survival endpoint by blinded central review in first-line EGFR exon 20 insertion NSCLC.
- The higher dose showed only a modest numerical edge over platinum chemotherapy and the lower dose did numerically worse, while investigator-assessed results looked more favorable.
- ArriVent's shares fell sharply on the news.
💡 Points
A small central-review margin over chemo, in a setting where J&J's Rybrevant-plus-chemo regimen has already set a higher bar, leaves firmonertinib hard to position in exon 20. The investigator-versus-central gap gives ArriVent a regulatory conversation but a thin commercial story. The PACC-mutation ALPACCA study now looks like the company's real value driver.